- Avidity Biosciences (RNA, Financial) grants 263,000 stock options and 131,450 RSUs under Nasdaq Listing Rule 5635(c)(4).
- Stock options have an exercise price of $26.66 and vest over four years.
- RSUs vest in four equal annual installments, requiring continued employment.
Avidity Biosciences, Inc. (RNA), a leader in RNA therapeutics, announced the issuance of new equity grants under its 2022 Employment Inducement Incentive Award Plan. In compliance with Nasdaq Listing Rule 5635(c)(4), the company has awarded 263,000 non-qualified stock options and 131,450 restricted stock units (RSUs) to 33 newly hired non-executive employees.
The stock options have an exercise price of $26.66 per share, equaling the closing price on Nasdaq Global Market on April 17, 2025. The options will vest over a period of four years, with 25% vesting after the first year, followed by monthly vesting over the subsequent 36 months, contingent upon continuous employment. Similarly, the RSUs will vest in four equal annual installments, also conditional on sustained employment at Avidity Biosciences.
Avidity's inducement grants are intended to attract and retain talent as part of the company's ongoing commitment to developing Antibody Oligonucleotide Conjugates (AOCsâ„¢) and advancing its innovative pipeline in RNA therapeutics. For more details on Avidity's groundbreaking work in biotechnology, visit their official website and follow their updates on LinkedIn and X.
